Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ikervis for quality of vision in severe dry eye disease with keratitis
2016-003497-40Phase 4Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jan 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cyclosporine in dry eye syndrome (DED) and keratitis, sponsored by Santen Pharmaceutical. Primary endpoint: Quality of vision. Started Jan 2017; status: completed.
02
Drugs
cyclosporine
03
Conditions
dry eye syndrome (DED)keratitis
Beyond the preview
Go deeper on 2016-003497-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003497-40.